Literature DB >> 9876564

Measurement of electrostatic charge decay in pharmaceutical powders and polymer materials used in dry powder inhaler devices.

P A Carter1, G Rowley, E J Fletcher, V Stylianopoulos.   

Abstract

The electrostatic charge generated on drug/excipient particles during the formulation, manufacture, and use of pharmaceutical dry powder inhaler (DPI) devices may significantly affect the performance of such devices. An experimental investigation has been undertaken of charge accumulation and decay on compacts of selected powders (lactose and salbutamol sulfate) and a device material (polyvinyl chloride, PVC) used during the formulation, manufacture, and use of DPIs. Significant differences in charge acquisition and decay for the three materials have been demonstrated after charging using a corona electrode. PVC acquired the highest charge, which decayed rapidly in 30 min toward the value prior to exposure to corona. Lactose and salbutamol acquired similar charge values, which decayed to zero after 30 min for lactose, whereas salbutamol retained a significant charge after 120 min. The significant differences in charging propensity among drug, excipient, and device materials may have relevance in DPI formulation, manufacture, and use.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9876564     DOI: 10.3109/03639049809089953

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  5 in total

1.  Optical feedback training of inhalation with Autohaler and Turbuhaler in COPD patients.

Authors:  J Steier; T Trammer; R M Cloes; W Petro
Journal:  Lung       Date:  2003       Impact factor: 2.584

2.  Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.

Authors:  V N P Le; T H Hoang Thi; E Robins; M P Flament
Journal:  AAPS PharmSciTech       Date:  2012-03-08       Impact factor: 3.246

Review 3.  In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases.

Authors:  Sau Lawrence Lee; Wallace P Adams; Bing V Li; Dale P Conner; Badrul A Chowdhury; Lawrence X Yu
Journal:  AAPS J       Date:  2009-06-03       Impact factor: 4.009

4.  Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Authors:  Kai-Michael Beeh; Anne-Marie Kirsten; Daniel Dusser; Ashish Sharma; Piet Cornelissen; Ralf Sigmund; Petra Moroni-Zentgraf; Ronald Dahl
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-09       Impact factor: 2.849

5.  Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder.

Authors:  Tushar Saha; Shubhra Sinha; Rhodri Harfoot; Miguel E Quiñones-Mateu; Shyamal C Das
Journal:  Pharmaceutics       Date:  2022-07-08       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.